Uroplasty Inc (UPI)

1.22
0.03 2.40
Prev Close 1.25
Open 1.26
Day Low/High 1.18 / 1.29
52 Wk Low/High 1.05 / 4.05
Volume 236.64K
Avg Volume 207.20K
Exchange
Shares Outstanding 22.15M
Market Cap 27.01M
EPS -0.25
Div & Yield N.A. (N.A)

Latest News

Uroplasty To Host Investor Meeting At Corporate Headquarters

Uroplasty To Host Investor Meeting At Corporate Headquarters

March 12th Event to Feature Urologist Perspective on the Use of Uroplasty and Vision-Sciences Product Lines

Insider Trading Alert - MD, OKSB And UPI Traded By Insiders

Insider Trading Alert - MD, OKSB And UPI Traded By Insiders

Stocks with insider trader activity include MD, OKSB and UPI

3 Stocks Pushing The Health Services Industry Lower

3 Stocks Pushing The Health Services Industry Lower

TheStreet highlights 3 stocks pushing the Health Services industry lower today.

UPI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Launches An Investigation Of The Board Of Directors Of Uroplasty, Inc. Regarding The Fairness Of The Sale Of The Company To Vision-Sciences, Inc. - UPI

UPI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Launches An Investigation Of The Board Of Directors Of Uroplasty, Inc. Regarding The Fairness Of The Sale Of The Company To Vision-Sciences, Inc. - UPI

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Uroplasty, Inc.

UROPLASTY, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Vision-Sciences, Inc.

UROPLASTY, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Vision-Sciences, Inc.

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Uroplasty, Inc.

Uroplasty And Vision-Sciences To Merge, Creating Medical Device Company Positioned For Growth

Uroplasty And Vision-Sciences To Merge, Creating Medical Device Company Positioned For Growth

All-Stock Combination Creates New Company with Expanded Product Offerings in Urology

Healthcare Industry Leader Kenneth H. Paulus Joins Uroplasty's Board Of Directors

Healthcare Industry Leader Kenneth H. Paulus Joins Uroplasty's Board Of Directors

Brings 30 Years of Healthcare Delivery System Leadership Experience to Uroplasty

Uroplasty Strengthens Board Of Directors With Addition Of Kevin H. Roche

Uroplasty Strengthens Board Of Directors With Addition Of Kevin H. Roche

~Roche Brings Deep Healthcare Industry and Business Strategy Experience

Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Independence Blue Cross

Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Independence Blue Cross

~Positive Coverage Decision Adds 2.2 Million Covered Lives for Up to Two Years of Treatment with Urgent PC

Uroplasty Appoints Suranjan Roychowdhury, Ph.D. To New Vice President Of Research & Development And Clinical Affairs Role

Uroplasty Appoints Suranjan Roychowdhury, Ph.D. To New Vice President Of Research & Development And Clinical Affairs Role

Experienced Executive in Development and Commercialization of Medical Devices to Assume Key New Position

Why Uroplasty (UPI) Hit A Two-Year High Today

Why Uroplasty (UPI) Hit A Two-Year High Today

Uroplasty (UPI) hits a two-year high of $5.40 on Friday after the company reported revenue of $6.4 million, up 14% from the same period one year earlier. Domestic sales of the company's Urgent PC Neuromodulation System grew 19% to $3.2 million, up from $2.7 million in the same quarter one year earlier. Domestic sales of Macroplastique grew 11% to $1.5 million, while net sales outside of the U.S. grew 11% to $1.6 million.